Jagsonpal Pharmaceuticals Intrinsic Value
JAGSNPHARM Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹202.40 | ₹161.92 - ₹242.88 | +10.7% | EPS: ₹9.20, Sector P/E: 22x |
| Book Value Method | asset | ₹369.23 | ₹332.31 - ₹406.15 | +102.0% | Book Value/Share: ₹184.62, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹365.52 | ₹328.97 - ₹402.07 | +100.0% | Revenue/Share: ₹243.85, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹365.52 | ₹328.97 - ₹402.07 | +100.0% | EBITDA: ₹89.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹456.90 | ₹365.52 - ₹548.28 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹54.83 | ₹49.35 - ₹60.31 | -70.0% | EPS Growth: 6.3%, Fair P/E: 5.1x |
| Growth Adjusted P/E | growth | ₹144.51 | ₹130.06 - ₹158.96 | -20.9% | Revenue Growth: 9.4%, Adj P/E: 15.7x |
| ROE Based Valuation | profitability | ₹365.52 | ₹328.97 - ₹402.07 | +100.0% | ROE: 25.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹195.49 | ₹175.94 - ₹215.04 | +7.0% | EPS: ₹9.20, BVPS: ₹184.62 |
Want to compare with current market value? Check JAGSNPHARM share price latest .
Valuation Comparison Chart
JAGSNPHARM Intrinsic Value Analysis
What is the intrinsic value of JAGSNPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jagsonpal Pharmaceuticals (JAGSNPHARM) is ₹365.52 (median value). With the current market price of ₹182.76, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹54.83 to ₹456.90, indicating ₹54.83 - ₹456.90.
Is JAGSNPHARM undervalued or overvalued?
Based on our multi-method analysis, Jagsonpal Pharmaceuticals (JAGSNPHARM) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.42 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.16 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 25.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.14x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Jagsonpal Pharmaceuticals
Additional stock information and data for JAGSNPHARM
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹55 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹35 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹47 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹7 Cr | ₹-6 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹28 Cr | ₹27 Cr | Positive Free Cash Flow | 8/10 |